{"title":"블로터 ─ 비즈니스 ─ 헤드라인","url":"https://www.bloter.net/section?id=sectionBusiness2","favicon":"https://www.bloter.net/favicon.png","elements":[{"title":"삼성바이오로직스, 美 바이오젠 결별 ‘왜?’…에피스 사업 타격받나","contents":"<span class=\"writer\">정두용</span>                        <span class=\"date\">2022-01-28 22:56:09</span>","link":"https://www.bloter.net/newsView/blt202201280262","retrieved":1643379246607,"image":"https://www.bloter.net/data/blt/image/2022/01/28/blt202201280064.570x320.0.jpg"},{"title":"2조7655억원 ‘빅딜’…삼성바이오로직스, 에피스 온전히 품었다","contents":"<span class=\"writer\">정두용</span>                        <span class=\"date\"></span>","link":"https://www.bloter.net/newsView/blt202201280241","retrieved":1643379246609},{"title":"‘영업익 83.5%’ 오른 삼성바이오로직스, 배당 도입 시사…부채 증가는 숙제","contents":"<span class=\"writer\">정두용</span>                        <span class=\"date\"></span>","link":"https://www.bloter.net/newsView/blt202201240091","retrieved":1643379246610},{"title":"②영업이익 늘었지만 '빚 의존' 커졌다","contents":"<span class=\"writer\">박현준</span>                        <span class=\"date\"></span>","link":"https://www.bloter.net/newsView/blt202201130078","retrieved":1643379246612},{"title":"삼성, 美 바이오젠 인수설 왜 나올까","contents":"<span class=\"writer\">최창원</span><span class=\"writer\">정두용</span>                        <span class=\"date\"></span>","link":"https://www.bloter.net/newsView/blt202112300029","retrieved":1643379246614}]}